Amedeo Smart

Free Medical Literature Service

 

Amedeo

Tuberculosis
  Free Subscription

Articles published in
J Infect Dis
    April 2024
  1. MORO RN, Mehaffy C, De P, Phillips E, et al
    Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-like Reactions During Treatment of Latent Tuberculosis Infection.
    J Infect Dis. 2024 Apr 19:jiae180. doi: 10.1093.
    >> Share

  2. CROSS GB, O' Doherty J, Chang CC, Kelleher AD, et al
    Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?
    J Infect Dis. 2024;229:1229-1238.
    >> Share

  3. TAIT D, Diacon A, Borges AH, van Brakel E, et al
    Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
    J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
    >> Share

    March 2024
  4. PATON NI, Gurumurthy M, Lu Q, Leek F, et al
    Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial.
    J Infect Dis. 2024 Mar 25:jiae104. doi: 10.1093.
    >> Share

  5. OLSSON O, Sokilde R, Tesfaye F, Karlson S, et al
    Tuberculosis disease is associated with elevated plasma ribonuclease activity in antiretroviral treatment-naive people with HIV.
    J Infect Dis. 2024 Mar 25:jiae143. doi: 10.1093.
    >> Share

    February 2024
  6. XIAO G, Huang W, Zhong Y, Ou M, et al
    Uncovering the Bronchoalveolar Single-Cell Landscape of Patients With Pulmonary Tuberculosis With Human Immunodeficiency Virus Type 1 Coinfection.
    J Infect Dis. 2024 Feb 27:jiae042. doi: 10.1093.
    >> Share

  7. OH IS, Kim JH, Huh K, Jang SH, et al
    Impact of National Public-Private Mix and Medical Expense Support Program for Control Tuberculosis in South Korea: An Interrupted Time Series Analysis.
    J Infect Dis. 2024 Feb 14:jiae059. doi: 10.1093.
    >> Share

  8. CHAUHAN KS, Dunlap MD, Akter S, Gupta A, et al
    NF-kappaB signaling deficiency in CD11c-expressing phagocytes mediates early inflammatory responses and enhances Mycobacterium tuberculosis control.
    J Infect Dis. 2024 Feb 7:jiae060. doi: 10.1093.
    >> Share

    January 2024
  9. ZHENG Q, Li Z, Zhou Y, Li Y, et al
    Heparin-binding hemagglutinin of Mycobacterium tuberculosis inhibits autophagy via TLR4 and drives M2 polarization in macrophages.
    J Infect Dis. 2024 Jan 24:jiae030. doi: 10.1093.
    >> Share

  10. PEI X, Zhong T, Yang C, Sun L, et al
    Cost-Effectiveness of Community-Based Active Case Finding Strategy for Tuberculosis: Evidence from Shenzhen, China.
    J Infect Dis. 2024 Jan 23:jiae024. doi: 10.1093.
    >> Share

  11. RIDOLFI F, Amorim G, Peetluk LS, Haas DW, et al
    Prediction models for adverse drug reactions during tuberculosis treatment in Brazil.
    J Infect Dis. 2024 Jan 23:jiae025. doi: 10.1093.
    >> Share

    December 2023
  12. ZAINABADI K, Vilbrun SC, Mathurin LD, Walsh KF, et al
    A bedaquiline, pyrazinamide, levofloxacin, linezolid, clofazimine second line regimen for tuberculosis displays similar early bactericidal activity as the standard rifampin based first line regimen.
    J Infect Dis. 2023 Dec 7:jiad564. doi: 10.1093.
    >> Share

    November 2023
  13. BLAZEVIC A, Edwards RL, Xia M, Eickhoff CS, et al
    Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guerin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    J Infect Dis. 2023 Nov 29:jiad441. doi: 10.1093.
    >> Share

  14. YUEN CM, Huang CC, Millones AK, Calderon RI, et al
    Utility of Mycobacterium tuberculosis genome sequencing snapshots to assess transmission dynamics over time.
    J Infect Dis. 2023 Nov 23:jiad515. doi: 10.1093.
    >> Share

    October 2023
  15. SINGH B, Pahuja I, Yadav P, Shaji A, et al
    Adjunct therapy with all-trans-retinoic acid improves therapeutic efficacy through immunomodulation while treating tuberculosis with antibiotics in a murine model.
    J Infect Dis. 2023 Oct 21:jiad460. doi: 10.1093.
    >> Share

    September 2023
  16. ESCUDERO JN, Mecha J, Richardson BA, Maleche-Obimbo E, et al
    Impact of HIV and peripartum period on Mycobacterium tuberculosis infection detection.
    J Infect Dis. 2023 Sep 28:jiad416. doi: 10.1093.
    >> Share

  17. ABDELGAWAD N, Wasserman S, Abdelwahab MT, Davis A, et al
    Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis.
    J Infect Dis. 2023 Sep 22:jiad413. doi: 10.1093.
    >> Share

  18. NORE KG, Louet C, Bugge M, Gidon A, et al
    The Cyclooxygenase 2 inhibitor etoricoxib as adjunctive therapy in tuberculosis impairs macrophage control of mycobacterial growth.
    J Infect Dis. 2023 Sep 18:jiad390. doi: 10.1093.
    >> Share

  19. RASI V, Phelps KR, Paulson KR, Eickhoff CS, et al
    Homodimeric Granzyme A opsonizes Mycobacterium tuberculosis and inhibits its intracellular growth in human monocytes via TLR4 and CD14.
    J Infect Dis. 2023 Sep 6:jiad378. doi: 10.1093.
    >> Share

    August 2023
  20. HILL PC, Cobelens F, Martinez L, Behr MA, et al
    An aspiration to radically shorten phase 3 TB vaccine trials.
    J Infect Dis. 2023 Aug 22:jiad356. doi: 10.1093.
    >> Share

  21. MCSHANE H
    Improving TB vaccine trial efficiency: A tough nut to crack.
    J Infect Dis. 2023 Aug 21:jiad360. doi: 10.1093.
    >> Share

    June 2023
  22. MAENETJE P, Baik Y, Schramm DB, Vangu MDW, et al
    Circulating biomarkers, FeNO, and lung function in patients with HIV and tuberculosis.
    J Infect Dis. 2023 Jun 30:jiad232. doi: 10.1093.
    >> Share

  23. SINGH DK, Bhaskar A, Pahuja I, Shaji A, et al
    Co-treatment with Clofazimine and Rapamycin eliminates drug-resistant tuberculosis by inducing polyfunctional central memory T cell responses.
    J Infect Dis. 2023 Jun 8:jiad214. doi: 10.1093.
    >> Share

    May 2023
  24. CHEN S, Li C, Qin Z, Song L, et al
    Serum metabolomic profiles for distinguishing lung cancer from pulmonary tuberculosis: identification of rapid and noninvasive biomarker.
    J Infect Dis. 2023 May 29:jiad175. doi: 10.1093.
    >> Share

  25. RAMALINGAM S, Kumar A, Krug S, Mohan H, et al
    CRISPR correction of GBA mutation in hiPSCs restores normal function to Gaucher macrophages and increases their susceptibility to Mycobacterium tuberculosis.
    J Infect Dis. 2023 May 9:jiad141. doi: 10.1093.
    >> Share

  26. BORBORA SM, Satish BA, Sundar S, B M, et al
    Mycobacterium tuberculosis elevates SLIT2 expression within the host and contributes to oxidative stress responses during infection.
    J Infect Dis. 2023 May 9:jiad126. doi: 10.1093.
    >> Share

    April 2023
  27. VAN DER HEIJDEN YF, Maruri F, Blackman A, Morrison R, et al
    Mycobacterium tuberculosis gene expression associated with fluoroquinolone resistance and efflux pump inhibition.
    J Infect Dis. 2023 Apr 20:jiad112. doi: 10.1093.
    >> Share

  28. ALEMNJI G, Mosha F, Maggiore P, Alexander H, et al
    Building Integrated Testing Programs for Infectious Diseases.
    J Infect Dis. 2023 Apr 12:jiad103. doi: 10.1093.
    >> Share

  29. ROCCO JM, Laidlaw E, Galindo F, Anderson M, et al
    Mycobacterial Immune Reconstitution Inflammatory Syndrome in HIV is Associated With Protein-Altering Variants in Hemophagocytic Lymphohistiocytosis-Related Genes.
    J Infect Dis. 2023 Apr 11:jiad059. doi: 10.1093.
    >> Share

    February 2023
  30. SABO MC, Thuong NTT, Chang X, Ardiansyah E, et al
    MUC5AC genetic variation is associated with tuberculous meningitis CSF cytokine responses and mortality.
    J Infect Dis. 2023 Feb 24:jiad050. doi: 10.1093.
    >> Share

  31. MEDRANO JM, Maiello P, Rutledge T, Tomko J, et al
    Characterizing the Spectrum of Latent Mycobacterium tuberculosis in the Cynomolgus Macaque Model: Clinical, Immunologic, and Imaging Features of Evolution.
    J Infect Dis. 2023;227:592-601.
    >> Share

    December 2022
  32. DONNELLAN S, Pennington SH, Ruggiero A, Martinez-Rodriguez C, et al
    A quantitative method for the study of HIV-1 and Mycobacterium tuberculosis co-infection.
    J Infect Dis. 2022 Dec 20:jiac491. doi: 10.1093.
    >> Share

    August 2022
  33. HAAS DW, Abdelwahab MT, van Beek SW, Baker P, et al
    Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa.
    J Infect Dis. 2022;226:147-156.
    >> Share

    May 2022
  34. KUA KP, Chongmelaxme B, Lee S
    Association between cytomegalovirus infection and tuberculosis disease: A systematic review and meta-analysis of epidemiological studies.
    J Infect Dis. 2022 May 4. pii: 6580085. doi: 10.1093.
    >> Share

  35. WALKER NF, Karim F, Moosa M, Moodley S, et al
    Elevated Plasma Matrix Metalloproteinase-8 associates with Sputum Culture Positivity in Pulmonary Tuberculosis.
    J Infect Dis. 2022 May 1. pii: 6576469. doi: 10.1093.
    >> Share

    March 2022
  36. NGO MD, Bartlett S, Bielefeldt-Ohmann H, Foo CX, et al
    A blunted GPR183/oxysterol axis during dysglycemia results in delayed recruitment of macrophages to the lung during M. tuberculosis infection.
    J Infect Dis. 2022 Mar 18. pii: 6550675. doi: 10.1093.
    >> Share

    February 2022
  37. TEPEKULE B, Kusejko K, Zeeb M, Tarr PE, et al
    Impact of Latent Tuberculosis Infection on the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study.
    J Infect Dis. 2022 Feb 16. pii: 6529706. doi: 10.1093.
    >> Share

  38. JIA P, Zhang Y, Xu J, Zhu M, et al
    IMB-BZ as an Inhibitor Targeting ESX-1 Secretion System to Control Mycobacterial Infection.
    J Infect Dis. 2022;225:608-616.
    >> Share

  39. AGARWAL S, Tiwari P, Deep A, Kidwai S, et al
    Corrigendum to: System-Wide Analysis Unravels the Differential Regulation and In Vivo Essentiality of Virulence-Associated Proteins B and C Toxin-Antitoxin Systems of Mycobacterium tuberculosis.
    J Infect Dis. 2022 Feb 11. pii: 6526953. doi: 10.1093.
    >> Share

    January 2022
  40. ZURCHER K, Riou J, Morrow C, Ballif M, et al
    Estimating Tuberculosis Transmission Risks in a Primary Care Clinic in South Africa: Modeling of Environmental and Clinical Data.
    J Infect Dis. 2022 Jan 18. pii: 6510424. doi: 10.1093.
    >> Share

    December 2021
  41. SAHA A, Escudero J, Layouni T, Richardson B, et al
    Mycobacterium tuberculosis-specific T cell responses are impaired during late pregnancy with elevated biomarkers of tuberculosis risk postpartum.
    J Infect Dis. 2021 Dec 20. pii: 6470923. doi: 10.1093.
    >> Share

  42. GERIC C, Saroufim M, Landsman D, Richard J, et al
    Impact of Covid-19 on Tuberculosis Prevention and Treatment in Canada: a multicentre analysis of 10,833 patients.
    J Infect Dis. 2021 Dec 17. pii: 6469005. doi: 10.1093.
    >> Share

  43. POERIO N, Caccamo N, La Manna MP, Olimpieri T, et al
    Phosphatidylserine liposomes reduce inflammatory response, mycobacterial viability and HIV replication in coinfected human macrophages.
    J Infect Dis. 2021 Dec 15. pii: 6463308. doi: 10.1093.
    >> Share

    November 2021
  44. HLAKA L, Ozturk M, Chia JE, Jones SS, et al
    IL-4i1 regulates immune protection during Mycobacterium tuberculosis infection.
    J Infect Dis. 2021 Nov 5. pii: 6421699. doi: 10.1093.
    >> Share

    October 2021
  45. ARRIAGA MB, Araujo-Pereira M, Barreto-Duarte B, Nogueira B, et al
    The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study.
    J Infect Dis. 2021 Oct 15. pii: 6398049. doi: 10.1093.
    >> Share

    September 2021
  46. LONG R, Lau A, Egedahl ML, Paulsen C, et al
    Local Transmission Plays No Important Role in the Occurrence of Multidrug-Resistant Tuberculosis in Immigrants to Canada: An In-depth Epidemiologic Analysis.
    J Infect Dis. 2021;224:1029-1038.
    >> Share

  47. PIETERMAN ED, Keutzer L, van der Meijden A, van den Berg S, et al
    Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.
    J Infect Dis. 2021;224:1039-1047.
    >> Share

  48. CHEN Y, Ji L, Liu Q, Li J, et al
    Lesion Heterogeneity and Long-Term Heteroresistance in Multidrug-Resistant Tuberculosis.
    J Infect Dis. 2021;224:889-893.
    >> Share

    July 2021
  49. HALLIDAY A, Masonou T, Tolosa-Wright MR, Guo Y, et al
    Defining the Role of Cellular Immune Signatures in Diagnostic Evaluation of Suspected Tuberculosis.
    J Infect Dis. 2021 Jul 31. pii: 6332782. doi: 10.1093.
    >> Share

    May 2021
  50. ARRIAGA MB, Rocha MS, Nogueira B, Nascimento V, et al
    The Effect of Diabetes and Prediabetes on Mycobacterium tuberculosis Transmission to Close Contacts.
    J Infect Dis. 2021 May 19. pii: 6278117. doi: 10.1093.
    >> Share

  51. PARVEEN S, Lun S, Urbanowski ME, Cardin M, et al
    Effective host-directed therapy for tuberculosis by targeted depletion of myeloid-derived suppressor cells and related cells using a diphtheria toxin-based fusion protein.
    J Infect Dis. 2021 May 6. pii: 6270734. doi: 10.1093.
    >> Share

    March 2021
  52. DUFFY FJ, Olson GS, Gold ES, Jahn A, et al
    A contained Mycobacterium tuberculosis mouse infection model predicts active disease and containment in humans.
    J Infect Dis. 2021 Mar 10. pii: 6167837. doi: 10.1093.
    >> Share

    February 2021
  53. MUDDE SE, Alsoud RA, van der Meijden A, Upton AM, et al
    Predictive modeling to study the treatment-shortening potential of novel tuberculosis drug regimens, towards bundling of preclinical data.
    J Infect Dis. 2021 Feb 19. pii: 6145049. doi: 10.1093.
    >> Share

  54. RAO MUVVA J, Ahmed S, Rekha RS, Kalsum S, et al
    Immunomodulatory agents combat multidrug-resistant tuberculosis by improving antimicrobial immunity.
    J Infect Dis. 2021 Feb 19. pii: 6145048. doi: 10.1093.
    >> Share

  55. DUBEY N, Khan MZ, Kumar S, Sharma A, et al
    Mycobacterium tuberculosis PPiA interacts with host integrin receptor to exacerbate disease progression.
    J Infect Dis. 2021 Feb 13. pii: 6134355. doi: 10.1093.
    >> Share

  56. LAI CC, Tehrani B, Yungtum G, Hsu WT, et al
    Association between the use of statins and risk of tuberculosis: a real-world analysis.
    J Infect Dis. 2021 Feb 8. pii: 6131374. doi: 10.1093.
    >> Share

  57. BEHR MA, Divangahi M, Schurr E
    Lessons From Bacille Calmette-Guerin for SARS-CoV-2 Vaccine Candidates.
    J Infect Dis. 2021;223:189-191.
    >> Share

    January 2021
  58. STEIN CM, Benchek P, Bartlett J, Igo RP, et al
    Methylome-wide analysis reveals epigenetic marks associated with resistance to tuberculosis in HIV-infected individuals from East Africa.
    J Infect Dis. 2021 Jan 5. pii: 6064776. doi: 10.1093.
    >> Share

    November 2020
  59. BARBOSA BOMFIM CC, Pinheiro Amaral E, Santiago-Carvalho I, Almeida Santos G, et al
    Granulocytic Myeloid-Derived Suppressor Cells Aggravate Tuberculosis Caused by Hypervirulent Mycobacteria.
    J Infect Dis. 2020 Nov 18. pii: 5989003. doi: 10.1093.
    >> Share

    October 2020
  60. DONOVAN J, Tram TTB, Phu NH, Hiep NTT, et al
    The influence of Strongyloides stercoralis co-infection on the presentation, pathogenesis and outcome of tuberculous meningitis.
    J Infect Dis. 2020 Oct 26. pii: 5940016. doi: 10.1093.
    >> Share

  61. HJORT K, Juren P, Toro JC, Hoffner S, et al
    Dynamics of extensive drug resistance evolution of Mycobacterium tuberculosis in a single patient during 9 years of disease and treatment.
    J Infect Dis. 2020 Oct 12. pii: 5921146. doi: 10.1093.
    >> Share

  62. AGARWAL S, Tiwari P, Deep A, Kidwai S, et al
    Corrigendum to: System-Wide Analysis Unravels the Differential Regulation and In Vivo Essentiality of Virulence-Associated Proteins B and C Toxin-Antitoxin Systems of Mycobacterium tuberculosis.
    J Infect Dis. 2020 Oct 7. pii: 5918919. doi: 10.1093.
    >> Share

    June 2020
  63. DUTTA NK, Karakousis PC
    Reply to Hu et al: Could there be detrimental effects of statin adjunctive TB therapy on immune responses?
    J Infect Dis. 2020;222:336-337.
    >> Share

    March 2020
  64. KAUSHAL D
    The Comeback Kid: BCG.
    J Infect Dis. 2020;221:1031-1032.
    >> Share

    January 2020
  65. CLICK ES, Kurbatova E, Alexander H, Dalton TL, et al
    Isoniazid- and Rifampin-Resistance Mutations Associated with Resistance to Second-line Drugs and with Sputum Culture Conversion.
    J Infect Dis. 2020 Jan 31. pii: 5718252. doi: 10.1093.
    >> Share

    December 2019
  66. HU Z, Lowrie DB, Fan XY
    Statins as adjunctive therapy against tuberculosisthe balance between statin-induced anti-TB effect and trained immunity suppression.
    J Infect Dis. 2019 Dec 24. pii: 5686380. doi: 10.1093.
    >> Share

    November 2019
  67. STOCKDALE L, Nash S, Farmer R, Raynes J, et al
    Cytomegalovirus antibody responses associated with increased risk of TB disease in Ugandan adults.
    J Infect Dis. 2019 Nov 5. pii: 5613526. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016